Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05295875 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of ALT-801 in the Treatment of Obesity
A Phase 2 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 391
- Enrollment target
NCT05295875 is a Phase 2 study that has completed, run by Altimmune. The registered enrollment target is 391 participants.
The verdict
NCT05295875, a Phase 2 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 391 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
Interventions
- OTHER Placebo
- DRUG ALT-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05295875
The ClinicalTrials.gov registry entry for NCT05295875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 391 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05295875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05295875 about?
NCT05295875 is a clinical study titled "Efficacy and Safety of ALT-801 in the Treatment of Obesity". This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
What is the current status of trial NCT05295875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 391 participants. The study started on 2022-03-31. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT05295875?
The interventions under investigation include: Placebo (OTHER), ALT-801 (DRUG).
Who is sponsoring clinical trial NCT05295875?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.